Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic NK Cells in R/R High-Risk Neuroblastoma
NCT06674265Phase 1Recruiting
- Sponsor
- Marzieh Ebrahimi
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic natural killer cells in neuroblastoma (2 arms), sponsored by Marzieh Ebrahimi. Primary endpoint: NK Cell Infusion Safety. Started Nov 2024; status: recruiting.
02
Drugs
allogeneic natural killer cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06674265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674265.